TGTX

TG Therapeutics, Inc.

17.78 USD
+0.80 (+4.71%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

TG Therapeutics, Inc. stock is up 0.45% since 30 days ago. The next earnings date is Jul 30, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 46.15% of the previous 12 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 10 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
03 Jun 19:05 17 Jan, 2025 7.00 CALL 50 2348
05 Jun 15:22 17 Jan, 2025 20.00 CALL 130 5354
05 Jun 18:17 17 Jan, 2025 22.00 CALL 130 895
07 Jun 15:00 17 Jan, 2025 10.00 CALL 50 6950
10 Jun 13:41 17 Jan, 2025 5.00 CALL 30 6400
10 Jun 19:27 17 Jan, 2025 5.00 CALL 45 6400
11 Jun 18:06 19 Jul, 2024 13.00 CALL 100 0
12 Jun 18:26 17 Jan, 2025 5.00 CALL 40 6325
13 Jun 14:26 15 Nov, 2024 9.00 CALL 50 1
17 Jun 19:51 16 Aug, 2024 21.00 CALL 500 376

About TG Therapeutics, Inc.

TG Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.